Blood Q1 Unclaimed
Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Acceptance of manuscripts is based on the originality and importance of the observations or investigations, the quality of the work and validity of the evidence, the clarity of presentation, and the relevance to our readership and field. All articles are expected to be concise, well organized and clearly written. It has an SJR impact factor of 5,272.
Blood focuses its scope in these topics and keywords: cell, cells, patients, leukemia, chronic, stem, t, blood, hematopoietic, human, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
3170 €
Inmediate OANPD
Embargoed OA910 €
Non OAMetrics
5,272
SJR Impact factor525
H Index819
Total Docs (Last Year)2623
Total Docs (3 years)25762
Total Refs20592
Total Cites (3 years)1657
Citable Docs (3 years)7.41
Cites/Doc (2 years)31.46
Ref/DocOther journals with similar parameters
Cell Research Q1
Molecular Cell Q1
Nature Cell Biology Q1
Nature Microbiology Q1
Annual Review of Plant Biology Q1
Compare this journals
Aims and Scope
Best articles by citations
HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy
View moreBusulfan bioavailability
View moreEpstein-Barr virus associated B-cell lymphoproliferation in an infant treated for acute lymphoblastic leukemia [letter]
View moreJAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma
View moreExpression and function of the endothelial protein C receptor in human neutrophils
View moreEvidence-based focused review of the role of radiation therapy in the treatment of early-stage Hodgkin lymphoma
View moreCidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
View moreTreating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome
View moreEosinophils are a major intravascular location for tissue factor storage and exposure
View moreGenetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma
View moreMonoclonal T-cell expansions in asymptomatic individuals and in patients with large granular leukemia consist of cytotoxic effector T cells expressing the activating CD94:NKG2C/E and NKD2D killer cell receptors
View moreIL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis
View moreIntravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes
View moreDermal and pulmonary inflammatory disease in E-selectin and P-selectin double-null mice is reduced in triple-selectin-null mice
View moreCell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor gamma-chain signaling and inhibited by cyclosporin A
View moreEnhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand
View moreGastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity
View moreFDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
View moreEvaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
View moreClonotypic B cells in classic Hodgkin lymphoma
View morePancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event
View moreAtypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma
View moreA phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
View moreImmunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma
View more
Comments